Read by QxMD icon Read


Christine Aroney, Samantha Fraser-Bell, Ecosse L Lamoureux, Mark C Gillies, Lyndell L Lim, Eva K Fenwick
Purpose: To determine the patient-centered effectiveness of treatment with the slow-release dexamethasone intravitreal implant (DEX implant) and intravitreal bevacizumab using the Impact of Vision Impairment Questionnaire (IVI), a vision-related quality of life (VRQoL) measure, in patients with visual impairment secondary to center-involving diabetic macular edema (DME). Methods: Patients with DME were enrolled in a phase 2, prospective, multicenter, randomized, single-masked clinical trial and received either DEX implant 4 monthly or bevacizumab monthly, both pro re nata...
October 1, 2016: Investigative Ophthalmology & Visual Science
Chenting Yan, Zhifang Li, Xu-Qiong Xiao, Ningka Wei, Qiong Lu, Mitsuo Kira
A fluorostannylenoid (Cs(+) [R2 SnF](-) (9), R2 =(TMS)2 CCH2 CH2 C(TMS)2 ) was prepared by reacting a stable dialkylstannylene (R2 Sn (8), R2 =(TMS)2 CCH2 CH2 C(TMS)2 ) with cesium fluoride at room temperature in THF. While 9 is stable in THF and DME, removal of the solvent leads to the regeneration of stannylene 8. No reaction occurred when 8 was treated with CsF in a hydrocarbon solvent. Addition of dibenzo-21-crown-7 ether to the THF solution of stannylenoid 9 followed by usual workup affords the corresponding crystalline stannylenoid crown ether complex, the X-ray structural analysis of which revealed a fluorine-bridged contact ion-pair structure...
October 20, 2016: Angewandte Chemie
Pedro Romero-Aroca, Marc Baget-Bernaldiz, Alicia Pareja-Rios, Maribel Lopez-Galvez, Raul Navarro-Gil, Raquel Verges
Diabetic macular edema (DME) can cause blindness in diabetic patients suffering from diabetic retinopathy (DR). DM parameters controls (glycemia, arterial tension, and lipids) are the gold standard for preventing DR and DME. Although the vascular endothelial growth factor (VEGF) is known to play a role in the development of DME, the pathological processes leading to the onset of this disease are highly complex and the exact sequence in which they occur is still not completely understood. Angiogenesis and inflammation have been shown to be involved in the pathogenesis of this disease...
2016: Journal of Diabetes Research
Yuji Itoh, Daniel Petkovsek, Peter K Kaiser, Rishi P Singh, Justis P Ehlers
BACKGROUND AND OBJECTIVE: To assess the relationship between spectral-domain optical coherence tomography (SD-OCT) features and functional outcomes for diabetic macular edema (DME) undergoing treatment with intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: Institutional review board-approved, retrospective, consecutive case series of eyes receiving intravitreal bevacizumab (1.25 mg) for DME. SD-OCT features were evaluated and correlated with functional response to anti-vascular endothelial growth factor (VEGF) therapy...
October 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
Kanako Yasuda, Ryosuke Motohashi, Osamu Kotake, Hayate Nakagawa, Hidetaka Noma, Masahiko Shimura
PURPOSE: To compare the effects of topical diclofenac and betamethasone on postoperative inflammation after combined sutureless cataract and vitreoretinal surgery in patients with macular hole (MH), epiretinal membrane (ERM), diabetic macular edema (DME), and rhegmatogenous retinal detachment (RRD). METHODS: The study involved 180 eligible eyes that underwent the combined surgery, followed by treatment with topical diclofenac (n = 100) or betamethasone (n = 80) for 12 weeks...
October 18, 2016: Journal of Ocular Pharmacology and Therapeutics
Wen Zhou, John Thompson, Clifford Leznoff, Daniel Bernard Leznoff
The preparation and structural characterization of a series of chromium phthalocyanine complexes with multiple metal and ring oxidation states was achieved using PcCr(II) (1) (Pc = phthalocyanine) or PcCr(II)(THF)2 (1·THF2) as starting material. The reaction of soluble 1·THF2 with Br2 or I2 gave the PcCr(III) halide complexes PcCrX(THF) (X= I/I3, Br) (3, 4). Treatment of 1 with one-half equivalent of PhIO or air generated the dinuclear [PcCr(THF)]2(μ-O) (5), while the addition of one equivalent of AgSbF6 to 1 resulted in oxidation to THF-solvated octahedral [PcCr(III)(THF)2]SbF6 (6)...
October 17, 2016: Chemistry: a European Journal
Takao Hirano, Yuichi Toriyama, Yasuhiro Iesato, Akira Imai, Kazutaka Hirabayashi, Taiji Nagaoka, Yoshihiro Takamura, Masahiko Sugimoto, Toshinori Murata
PURPOSE: The effect of combination therapy using intravitreal ranibizumab (IVR) injections and short pulse focal/grid laser photocoagulation was evaluated for the treatment of diabetic macular edema (DME). METHODS: The current investigation was a preliminary single-arm, open-label, prospective clinical study conducted on 21 eyes at 4 sites in Japan. Treatment protocol consisted of two phases. The induction IVR phase included two monthly IVRs followed by PRN IVR phase in which additional IVR was administered if the central macular thickness (CMT) exceeded 300 μm...
October 11, 2016: Japanese Journal of Ophthalmology
Jae Hyung Lee, Won Ki Lee, Sung Eun Kim
PURPOSE: To evaluate the efficacy of switching from bevacizumab to ranibizumab in patients with diabetic macular edema (DME). METHODS: Patients with DME who showed persistent fluid after at least 3 monthly bevacizumab injections were administered a single ranibizumab injection and were followed up after 1 month. Anatomic responders to ranibizumab were followed up monthly and administered ranibizumab injections on an as-needed basis for 3 months. RESULTS: At the 1-month follow-up, mean central subfield foveal thickness (CSFT) decreased from 422 to 346 μm (P < 0...
October 11, 2016: Journal of Ocular Pharmacology and Therapeutics
Yuichiro Ogura, Fumio Shiraga, Hiroko Terasaki, Masahito Ohji, Susumu Ishida, Taiji Sakamoto, Akito Hirakata, Tatsuro Ishibashi
PURPOSE: To elucidate the current clinical practice patterns of diabetic macular edema (DME) management by retinal specialists in Japan in the era of anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Forty-six retinal specialists were administered a survey regarding the pathology and clinical practice of DME. RESULTS: Nearly, half of the specialists (45.2 %) think that the main biochemical factor involved in DME development is the vascular permeability-potentiating action of VEGF-A...
October 8, 2016: Japanese Journal of Ophthalmology
Therese Granström, Henrietta Forsman, Anna Lindholm Olinder, Dimitrios Gkretsis, Jan W Eriksson, Elisabet Granstam, Janeth Leksell
AIMS: To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment due to diabetic macular edema (DME) during 12months in a real world setting. METHODS: In this cross-sectional study, 58 patients (29 females and 29 males; mean age, 68years) with type 1 and type 2 diabetes diagnosed with DME were included...
September 21, 2016: Diabetes Research and Clinical Practice
Robert G Bing-You, Kalli Varaklis
BACKGROUND: A new organizational model of educational administrative support was instituted in the Department of Medical Education (DME) to better meet increasing national accreditation demands. Residency and fellowship programs were organized into four 'Communities of Practice' (CoOPs) based on discipline similarity, number of learners, and geographic location. Program coordinator reporting lines were shifted from individual departments to a centralized reporting structure within the DME...
2016: Medical Education Online
Lee M Jampol, Adam R Glassman, Neil M Bressler, John A Wells, Allison R Ayala
Importance: Post hoc analyses from the Diabetic Retinopathy Clinical Research Network randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME) might influence interpretation of study results. Objective: To provide additional outcomes comparing 3 anti-vascular endothelial growth factor (VEGF) agents for DME. Design, Setting, and Participants: Post hoc analyses performed from May 3, 2016, to June 21, 2016, of a randomized clinical trial performed from August 22, 2012, to September 23, 2015, of 660 participants comparing 3 anti-VEGF treatments in eyes with center-involved DME causing vision impairment...
October 6, 2016: JAMA Ophthalmology
Yasir J Sepah, Mohammad Ali Sadiq, David Boyer, David Callanan, Ron Gallemore, Michael Bennett, Dennis Marcus, Lawrence Halperin, Muhammad Hassan, Peter A Campochiaro, Quan Dong Nguyen, Diana V Do
PURPOSE: To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME). DESIGN: Randomized, controlled, double-masked (to the dose), interventional, multicenter clinical trial. PARTICIPANTS: A total of 152 patients (152 eyes) with DME. METHODS: Eligible eyes were randomized in a 1:1 ratio to 0.5 mg (n = 77) or 2.0 mg (n = 75) RBZ. Study eyes received 6 monthly mandatory injections followed by as-needed injections until month 24...
October 1, 2016: Ophthalmology
Charles C Wykoff, Ryan T Le, Rahul N Khurana, David M Brown, William C Ou, Rui Wang, W Lloyd Clark, David S Boyer
PURPOSE: To determine whether the efficacy and safety achieved with 2.0mg intravitreal aflibercept injections (IAI) for diabetic macular edema (DME) during the phase III VISTA DME trial were maintained with individualized, as-needed treatment. DESIGN: Phase IV, multicenter, open-label extension study. METHODS: Sixty patients completing VISTA DME elected to enter the ENDURANCE extension study. All patients received IAI in the presence of clinically relevant DME...
October 1, 2016: American Journal of Ophthalmology
Undurti N Das
Diabetic macular edema (DME) and diabetic retinopathy (DR) are complications affecting about 25% of all patients with long-standing type 1 and type 2 diabetes mellitus and are a major cause of significant decrease in vision and quality of life. Age-related macular degeneration (AMD) is not uncommon, and diabetes mellitus affects the incidence and progression of AMD through altering hemodynamics, increasing oxidative stress, accumulating advanced glycation end products, etc. Recent studies suggest that DME, DR and AMD are inflammatory conditions characterized by a breakdown of the blood-retinal barrier, inflammatory processes and an increase in vascular permeability...
October 1, 2016: Archives of Medical Science: AMS
Roel Vermeulen, Lützen Portengen
OBJECTIVES: Recently, diesel motor exhaust (DME) has been classified as a known human carcinogen. We used data from epidemiological studies of diesel exposures to perform a quantitative risk assessment to calculate DME exposure levels, expressed as elemental carbon (EC), corresponding to acceptable risk (AR) and maximum tolerable risk (MTR) levels of 4 to 10(-5) and 4 to 10(-3) for the lifetime excess probability of dying from lung cancer. METHODS: Previously published slope estimates (n=14) of the exposure-response curve (ERC) for EC exposure and lung cancer were used in life-table analyses to calculate EC exposure levels corresponding to the specified AR and MTR levels...
September 28, 2016: Occupational and Environmental Medicine
Stela Vujosevic, Silvia Bini, Tommaso Torresin, Marianna Berton, Giulia Midena, Raffaele Parrozzani, Ferdinando Martini, Porzia Pucci, Anna R Daniele, Fabiano Cavarzeran, Edoardo Midena
PURPOSE: To evaluate hyperreflective retinal spots (HRS), in normal subjects and diabetic patients without and with macular edema (diabetic macular edema, DME), on linear B-scans and corresponding en face image of spectral-domain optical coherence tomography. METHODS: Retrospective evaluation of images of 54 eyes/subjects (16 normal subjects, 19 diabetic patients without DME, and 19 with DME). On horizontal B-scan spectral-domain optical coherence tomography, passing through the center of the fovea, the following characteristics of HRS were evaluated: location (inner retina or outer retina), size (≤30 or >30 μm), reflectivity (similar to nerve fiber layer or to retinal pigment epithelium-Bruch complex), and presence or absence of back shadowing...
September 23, 2016: Retina
Nancy M Holekamp
Diabetic retinopathy (DR) is both the leading cause of blindness among adults aged 20 to 74 in the United States, and the leading ocular complication associated with diabetes mellitus (DM). An estimated 4.4% of adults with DM over 40 years of age have the more advanced form of DR: diabetic macular edema (DME), which significantly increases the risk of blindness. Medical costs for Medicare patients with DME are a third higher than for patients without DME. The majority of these costs stem from other DM-related complications, as DME is a marker for poorly controlled DM overall...
July 2016: American Journal of Managed Care
Seenu M Hariprasad
Three modalities have a role in the primary management of diabetic macular edema (DME): laser photocoagulation, intravitreal vascular endothelial growth factor (VEGF) inhibitors, and intravitreal corticosteroid implants. Intravitreal VEGF inhibitors are most commonly used for center-involved DME, but laser photocoagulation and intravitreal corticosteroids also have an important role in DME management. Until recently, the selection of a VEGF inhibitor for a patient was complicated by a lack of comparative data and a much lower cost for bevacizumab compared with other agents...
July 2016: American Journal of Managed Care
Nancy M Holekamp
Diabetes mellitus (DM) is a rapidly growing epidemic in the United States, and it is expected to affect 592 million individuals within the next 20 years. Diabetic retinopathy (DR) and diabetic macular edema (DME) are the 2 most common ophthalmic complications of DM. DR is the leading cause of blindness among working-age adults around the world, and development of DR is tied to DM disease duration. With the only identifier of early markers of DR being a complete ophthalmic exam, early signs of the disease are asymptomatic...
July 2016: American Journal of Managed Care
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"